Apollomics (APLM) vs Biomea Fusion (BMEA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Apollomics (APLM) has outperformed Biomea Fusion (BMEA) over the past year, losing 42.4% versus a loss of 42.5%. Biomea Fusion is the larger company by market cap ($62.8 million vs $61.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | BMEA |
|---|---|---|
| Share price | $21.10 | $0.8689 |
| Market cap | $61.51M | $62.82M |
| 1-day change | -0.00% | +3.89% |
| YTD return | +12.86% | -29.93% |
| 1-year return | -42.43% | -42.46% |
| 5-year return | — | -92.09% |
| EPS (TTM) | $-7.57 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-53.86M | $-61.80M |
| 52-week high | $36.53 | $2.24 |
| 52-week low | $10.01 | $0.7995 |
| Distance from 52-week high | -42.23% | -61.16% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +705.62% |
| Average volume | 15.35K | 1.93M |
| Shares outstanding | 2.91M | 72.30M |
| Employees | 14 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apollomics
APLM stock →Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
APLM vs BMEA FAQ
Which is bigger, Apollomics or Biomea Fusion?
Biomea Fusion (BMEA) is larger, with a market capitalization of $62.82M compared with $61.51M for Apollomics (APLM).
Which stock has performed better over the past year, APLM or BMEA?
APLM returned -42.43% over the past 12 months, compared with -42.46% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and Biomea Fusion in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.